Volume 19, Number 3—March 2013
CME ACTIVITY - Research
Clinical and Therapeutic Features of Pulmonary Nontuberculous Mycobacterial Disease, Rio de Janeiro, Brazil
|Species||Treatment regimen (%)†|
|Mycobacterium avium complex||Clarithromycin, amikacin,ethambutol, rifampin (54.7)|
|Clarithromycin, ethambutol,quinolone, terizidon (28.3)|
|Clarithromycin, amikacin, ethambutol, quinolone‡ (17.0)
|Mycobacterium kansasii||Rifampin, ethambutol, isoniazid (52.5)|
|Rifampin, ethambutol, isoniazid, clarithromycin, amikacin (47.5)
|M. abscessus||Clarithromycin, amikacin (68.4)|
|Clarihromycin, amikacin, doxycycline (10.5)|
|Clarithromycin, amikacin, terizidon (21)
|M. massiliense||Clarithromycin, amikacin (33.3)|
|Clarithromycin, amikacin, terizidon (33.3)|
|Clarithromycin, amikacin, imipenem, tigeciclin (33.3)
|M. fortuitum||Clarithromycin, amikacin, quinolone (64.2)|
|Clarithromycin, amikacin, terizidon (28.5)|
|Clarithromycin, amikacin, quinolone, doxycycline (7.3)|
*ATS, AmericanThoracic Society; PNTM, pulmonary nontuberculous mycobacterial disease.
†Median duration of treatment, 19 mo.
‡Quinolones: levofloxacin, ciprofloxacin, moxifloxacin, ofloxacin.
Page created: February 13, 2013
Page updated: February 22, 2013
Page reviewed: February 22, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.